Contribution of the activities of CYP3A, CYP2D6, CYP1A2 and other potential covariates to the disposition of methadone in patients undergoing methadone maintenance treatment-Reference-Cited by-同舟云学术

Contribution of the activities of CYP3A, CYP2D6, CYP1A2 and other potential covariates to the disposition of methadone in patients undergoing methadone maintenance treatment

Published:2009-01 Issue:1 Volume:67 Page:29-37
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:

Author:

Shiran Mohammad-Reza,Lennard Martin S.,Iqbal Mohammad-Zafar,Lagundoye Oldwale,Seivewright Nicholas,Tucker Geoffrey T.,Rostami-Hodjegan Amin

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2125.2008.03312.x/fullpdf

Reference73 articles.

1. Pharmacokinetics of methadone and its primary metabolite in 20 opiate addicts;De Vos;Eur J Clin Pharmacol,1995

2. Dose-response effects of methadone in the treatment of opioid dependence;Strain;Ann Intern Med,1993

3. Moderate- vs high-dose methadone in the treatment of opioid dependence: a randomized trial;Strain;JAMA,1999

4. A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence;Ling;Arch Gen Psychiatry,1996

5. Rated well-being in relation to plasma concentrations of l- and d-methadone in satisfied and dissatisfied patients on methadone maintenance treatment;Hiltunen;Psychopharmacology (Berl),1999

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Methadone pharmacokinetics in opioid agonist treatment: Influencing factors and clinical implications;Basic & Clinical Pharmacology & Toxicology;2024-01-15

2. Predicting disruptions to drug pharmacokinetics and the risk of adverse drug reactions in non-alcoholic steatohepatitis patients;Acta Pharmaceutica Sinica B;2023-01

3. Pain and Genetic Connections;Encyclopedia of Quality of Life and Well-Being Research;2023

4. Available Agents: Contraindications and Potential Drug–Drug Interactions;Hepatitis C: Care and Treatment;2021

5. Drug–drug interactions with direct‐acting antivirals: when do we need to care?;Clinical Dilemmas in Viral Liver Disease;2020-03-20